Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Homosexuality, Male | 15 | 2020 | 483 | 1.650 |
Why?
|
| HIV Infections | 25 | 2022 | 2535 | 1.640 |
Why?
|
| Sexual Partners | 10 | 2020 | 325 | 1.500 |
Why?
|
| Self Care | 6 | 2020 | 173 | 1.220 |
Why?
|
| Mass Screening | 8 | 2020 | 531 | 1.120 |
Why?
|
| AIDS Serodiagnosis | 5 | 2020 | 25 | 1.080 |
Why?
|
| Self-Examination | 3 | 2020 | 9 | 1.000 |
Why?
|
| Sexual Behavior | 11 | 2020 | 634 | 0.870 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2021 | 72 | 0.820 |
Why?
|
| Puerto Rico | 18 | 2021 | 1376 | 0.700 |
Why?
|
| Syphilis | 1 | 2021 | 24 | 0.680 |
Why?
|
| Aggression | 1 | 2020 | 101 | 0.620 |
Why?
|
| Violence | 1 | 2020 | 133 | 0.610 |
Why?
|
| Anti-HIV Agents | 5 | 2022 | 475 | 0.570 |
Why?
|
| New York | 4 | 2020 | 88 | 0.410 |
Why?
|
| Anti-Infective Agents | 3 | 2017 | 74 | 0.350 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2020 | 13 | 0.340 |
Why?
|
| Gels | 5 | 2016 | 43 | 0.320 |
Why?
|
| Dengue Vaccines | 2 | 2020 | 15 | 0.300 |
Why?
|
| Adult | 23 | 2022 | 13458 | 0.290 |
Why?
|
| Female | 22 | 2022 | 24018 | 0.280 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2016 | 471 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 959 | 0.270 |
Why?
|
| Dengue | 2 | 2020 | 100 | 0.270 |
Why?
|
| Male | 23 | 2020 | 22779 | 0.260 |
Why?
|
| Lubricants | 2 | 2016 | 4 | 0.260 |
Why?
|
| Humans | 30 | 2022 | 42163 | 0.250 |
Why?
|
| New York City | 3 | 2020 | 283 | 0.230 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2014 | 14 | 0.220 |
Why?
|
| Pregnancy | 5 | 2022 | 1737 | 0.210 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2022 | 112 | 0.210 |
Why?
|
| Young Adult | 14 | 2020 | 4936 | 0.210 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2016 | 172 | 0.210 |
Why?
|
| Interviews as Topic | 6 | 2020 | 428 | 0.190 |
Why?
|
| Qualitative Research | 6 | 2020 | 526 | 0.170 |
Why?
|
| Administration, Rectal | 5 | 2016 | 18 | 0.150 |
Why?
|
| Dengue Virus | 1 | 2020 | 89 | 0.150 |
Why?
|
| Condoms | 1 | 2020 | 148 | 0.150 |
Why?
|
| HIV Seropositivity | 1 | 2020 | 196 | 0.150 |
Why?
|
| Adolescent | 11 | 2020 | 5950 | 0.150 |
Why?
|
| Unsafe Sex | 1 | 2020 | 162 | 0.150 |
Why?
|
| Mothers | 1 | 2021 | 212 | 0.140 |
Why?
|
| Risk-Taking | 3 | 2020 | 456 | 0.140 |
Why?
|
| Adaptation, Psychological | 2 | 2015 | 410 | 0.140 |
Why?
|
| Medical Informatics | 1 | 2017 | 24 | 0.130 |
Why?
|
| Postpartum Period | 3 | 2022 | 91 | 0.130 |
Why?
|
| Motivation | 1 | 2020 | 492 | 0.130 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2015 | 11 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 158 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 131 | 0.120 |
Why?
|
| Medication Adherence | 2 | 2014 | 177 | 0.110 |
Why?
|
| Caregivers | 2 | 2015 | 195 | 0.110 |
Why?
|
| Family | 1 | 2015 | 192 | 0.110 |
Why?
|
| Telemedicine | 1 | 2017 | 215 | 0.100 |
Why?
|
| Proteins | 1 | 2016 | 383 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2022 | 1574 | 0.100 |
Why?
|
| Community Health Services | 1 | 2014 | 207 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 825 | 0.100 |
Why?
|
| Social Support | 1 | 2015 | 438 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 273 | 0.090 |
Why?
|
| Alanine | 2 | 2022 | 33 | 0.090 |
Why?
|
| Middle Aged | 4 | 2020 | 11819 | 0.090 |
Why?
|
| Adenine | 2 | 2022 | 48 | 0.090 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2011 | 4 | 0.090 |
Why?
|
| Polylysine | 1 | 2011 | 9 | 0.090 |
Why?
|
| Herpesvirus 2, Human | 1 | 2011 | 9 | 0.090 |
Why?
|
| Quality of Life | 1 | 2015 | 599 | 0.090 |
Why?
|
| Vagina | 1 | 2011 | 89 | 0.090 |
Why?
|
| Pennsylvania | 3 | 2015 | 43 | 0.090 |
Why?
|
| Placebos | 3 | 2016 | 41 | 0.080 |
Why?
|
| Serologic Tests | 2 | 2020 | 45 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 163 | 0.080 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 137 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 358 | 0.070 |
Why?
|
| Antibodies, Neutralizing | 2 | 2020 | 118 | 0.070 |
Why?
|
| Patient Preference | 2 | 2020 | 55 | 0.070 |
Why?
|
| Risk | 2 | 2020 | 289 | 0.070 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 295 | 0.060 |
Why?
|
| Boston | 2 | 2015 | 31 | 0.060 |
Why?
|
| Prevalence | 3 | 2020 | 1597 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1051 | 0.060 |
Why?
|
| Social Adjustment | 1 | 2004 | 30 | 0.050 |
Why?
|
| Disclosure | 1 | 2004 | 36 | 0.050 |
Why?
|
| Administration, Intravaginal | 2 | 2014 | 8 | 0.050 |
Why?
|
| Neonatal Screening | 1 | 2002 | 24 | 0.050 |
Why?
|
| Puerperal Disorders | 1 | 2002 | 15 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2022 | 53 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2002 | 48 | 0.050 |
Why?
|
| Placenta | 1 | 2021 | 113 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2022 | 189 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 1221 | 0.040 |
Why?
|
| Attitude | 1 | 2020 | 108 | 0.040 |
Why?
|
| Gender Identity | 1 | 2020 | 117 | 0.040 |
Why?
|
| United States | 3 | 2015 | 5072 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2018 | 25 | 0.040 |
Why?
|
| Vaccines, Inactivated | 1 | 2018 | 16 | 0.040 |
Why?
|
| Vaccines, Attenuated | 1 | 2018 | 75 | 0.030 |
Why?
|
| Voice | 1 | 2017 | 4 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2015 | 960 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 117 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 3077 | 0.030 |
Why?
|
| Child | 2 | 2021 | 3381 | 0.030 |
Why?
|
| Rectum | 1 | 2016 | 27 | 0.030 |
Why?
|
| Sentinel Surveillance | 1 | 2016 | 24 | 0.030 |
Why?
|
| Herpes Genitalis | 1 | 2016 | 6 | 0.030 |
Why?
|
| Health Behavior | 1 | 2020 | 568 | 0.030 |
Why?
|
| HIV-1 | 1 | 2002 | 747 | 0.030 |
Why?
|
| Love | 1 | 2015 | 6 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 256 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 305 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 230 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2016 | 199 | 0.030 |
Why?
|
| Proteomics | 1 | 2016 | 363 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 574 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1001 | 0.020 |
Why?
|
| Coitus | 1 | 2011 | 12 | 0.020 |
Why?
|
| Dendrimers | 1 | 2011 | 15 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2015 | 641 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2011 | 1586 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2007 | 358 | 0.020 |
Why?
|
| Risk Factors | 1 | 2014 | 3942 | 0.020 |
Why?
|
| Schools, Medical | 1 | 2007 | 208 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 225 | 0.010 |
Why?
|
| HIV Antibodies | 1 | 2002 | 24 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 456 | 0.010 |
Why?
|
| Viral Load | 1 | 2002 | 344 | 0.010 |
Why?
|
| Time Factors | 1 | 2002 | 1848 | 0.010 |
Why?
|